The Tg.Ac (v-Ha-ras) transgenic mouse: Nature of the model

Toxicologic Pathology

Volumn 29, Issue SUPPL., 2001, Pages 51-59

  Tennant, R W ^a   Stasiewicz, S ^a   Eastin, W C ^a   Mennear, J H ^a   Spalding, J W ^a  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

Alternative carcinogen bioassay; Chemical carcinogens; Ras gene; Transgenic mouse

Indexed keywords

CARCINOGEN;

ANIMAL MODEL; BIOASSAY; CANCER INCIDENCE; CARCINOGEN TESTING; CONFERENCE PAPER; GENE EXPRESSION; GENOME; GENOTOXICITY; ONCOGENE H RAS; PHENOTYPE; PRIORITY JOURNAL; SKIN PAPILLOMA; TRANSGENE; TRANSGENIC MOUSE;

ACADEMIES AND INSTITUTES; ADMINISTRATION, TOPICAL; ANIMAL TESTING ALTERNATIVES; ANIMALS; CARCINOGENICITY TESTS; CARCINOGENS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENES, RAS; HUMANS; MALE; MICE; MICE, TRANSGENIC; PAPILLOMA; SKIN NEOPLASMS; SOCIETIES, SCIENTIFIC;

ANIMALIA; MUS MUSCULUS;

EID: 0034749117     PISSN: 01926233     EISSN: None     Source Type: Journal    
DOI: 10.1080/019262301753178474     Document Type: Conference Paper

References (32)

1. Definitive relationships among chemical structure, carcinogenicity and mutagenicity for 301 chemicals tested by the U.S. NTP
2. Dermal carcinogenicity in transgenic mice: Relative responsiveness of male and female hemizygous and homozygous Tg.AC mice to 12-0-tetradecanoylphorbol 13-acetate (TPA) and benzene
3. All in the family? New insights and questions regarding interconnectivity of Ras, Rap1, and Ral
4. Kinetics of wound-induced v-Ha-ras transgene expression and papilloma development in transgenic Tg.AC mice
5. Oral administration of dimethylvinyl chloride increases frequency of forestomach papillomas in Tg.AC mice
6. Statistical analysis of skin tumor data from Tg.AC mouse bioassays
7. The National Toxicology Program evaluation of genetically altered mice as predictive models for identifying carcinogens
8. Arsenic enhancement of skin neoplasia by chronic stimulation of growth factors
9. Neuropathologic findings associated with seizures in FVB mice
10. Association of tumor development with increased cellular proliferation and transgene overexpression but not c-Ha-ras mutations, in v-Ha-ras transgenic Tg.AC mice
11. 1 mice in two-year carcinogenicity studies: A National Toxicology Program update
12. Hemizygous Tg.AC transgenic mouse as a potential alternative to the two-year mouse carcinogenicity bioassay: Evaluation of husbandry and housing factors
13. Radial transformation-associated recombination cloning from the mouse genome: Isolation of Tg.AC transgene with flanking DNAs
14. v-Ha-ras transgene abrogates the initiation step in mouse skin tumorigenesis: Effects of phorbol esters and retinoic acid
15. Spontaneous lesions in aging FVB/N mice
16. Spontaneous and chemically induced proliferative lesions in Tg.AC transgenic and p53-heterozygous mice
17. Mutations in the ras proto-oncogene: Clues to etiology and molecular pathogenesis of mouse liver tumors
18. The International Life Sciences Institute's role in the evaluation of alternative methodologies for the assessment of carcinogenic risk
19. Comparative xenobiotic metabolism between Tg.AC and p53 +/- genetically altered mice and the respective wildtypes
20. Strain differences and solvent effects in mouse skin carcinogenesis experiments using carcinogens, tumor initiators and promoters
21. Chemically induced skin carcinogenesis in a transgenic mouse line (Tg.AC) carrying a v-Ha-ras gene
22. Development of a transgenic mouse model for carcinogenesis bioassays: Evaluation of chemically induced skin tumors in Tg.AC mice
23. Responses of transgenic mouse lines p53(deficient) and Tg.AC to agents tested in conventional carcinogenicity bioassays
24. Identifying chemical carcinogens and assessing potential risk in short-term bioassays using transgenic mouse models
25. Genetically alterd mouse models for identifying carcinogens
26. An evaluation of the hemizygous transgenic Tg.AC mouse for carcinogenicity testing of pharmaceuticals. II. A genotypic marker that predicts tumorigenic responsiveness
27. Photocarcinogenesis and susceptibility to UV radiation in the v-Ha-ras transgenic Tg.AC mouse
28. Carcinogenicity of epoxides, lactones, and peroxy compounds. VI. Structure and carcinogenic activity
29. Cancer etiology: Agents causally associated with human cancer
30. An evaluation of the hemizygous transgenic Tg.AC mouse for carcinogenicity testing of pharmaceuticals. I. Evidence for a confounding nonresponder phenotype
31. Odontogenic tumors in the v-Ha-ras (Tg.AC) transgenic mouse